DSwiss Inc (DQWS): M&A transaction — DSwiss (HK) acquires remaining 60% of DSwiss Biotech for nominal RM1

DSwiss Inc

Acquired 150,000 shares (60%) of DSwiss Biotech Sdn Bhd from shareholder Jervey Choon on Jan 18, 2023.
Purchase price: nominal fee of RM1 (approx. $0.23).
DSBT supplies biotech products in Malaysia with in-house R&D.
DSwiss (HK) now owns 100% of DSBT; acquisition closed as of Jan 18, 2023.
No material financial impact disclosed; consideration is trivial.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

DSwiss Inc completed an acquisition involving Jervey Choon for USD 0.23 (closed 2023-01-18).

Action: acquisition
Counterparty: Jervey Choon
Consideration: USD 0.23
Closing: 2023-01-18

Exact text from the filing

DSwiss Biotech Sdn Bhd from a shareholder, Jervey Choon, pursuant to which DSHK acquired 100% of DSBT. As consideration thereof, DSHK agreed to make the proceeds payment of USD 0.23 to the shareholder. DSwiss Biotech Sdn Bhd primarily operates in Malaysia by supplying biotech products to their clients as set forth below: Name Business Description DSwiss

View on SEC.gov

Browse all m&a transactions →

DSwiss Inc filing history →

Source: SEC EDGAR

accession 0001493152-23-001963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.